Evidence map›Paper›PMID 37672526›Full record

ArticlePLoS computational biology2023

Predictive modeling of antibiotic eradication therapy success for new-onset Pseudomonas aeruginosa pulmonary infections in children with cystic fibrosis.

Lucía Graña-Miraglia, Nadia Morales-Lizcano, Pauline W Wang, David M Hwang, Yvonne C W Yau, Valerie J Waters, David S Guttman

Open access · goldAbstract read
In one paragraph

Article in PLoS computational biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Therapeutic Interventions forJournal of clinical medicine · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Lucía Graña-MiragliaDepartment of Cell and Systems Biology, University of Toronto, Toronto, Ontario, Canada.
Nadia Morales-LizcanoDepartment of Cell and Systems Biology, University of Toronto, Toronto, Ontario, Canada.
Pauline W WangDepartment of Cell and Systems Biology, University of Toronto, Toronto, Ontario, Canada.
David M HwangDepartment of Laboratory Medicine and Pathobiology, Toronto, Ontario, Canada.
Yvonne C W YauDepartment of Laboratory Medicine and Pathobiology, Toronto, Ontario, Canada.
Valerie J WatersDepartment of Pediatrics, Division of Infectious Diseases, The Hospital for Sick Children, Toronto, Ontario, Canada.
David S GuttmanDepartment of Cell and Systems Biology, University of Toronto, Toronto, Ontario, Canada.ORCID 0000-0001-8479-3869
University of Toronto · CAHospital for Sick Children · CASunnybrook Health Science Centre · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic Pseudomonas aeruginosa (Pa) lung infections are the leading cause of mortality among cystic fibrosis (CF) patients; therefore, the eradication of new-onset Pa lung infections is an important therapeutic goal that can have long-term health benefits. The use of early antibiotic eradication therapy (AET) has been shown to clear the majority of new-onset Pa infections, and it is hoped that identifying the underlying basis for AET failure will further improve treatment outcomes. Here we generated machine learning models to predict AET outcomes based on pathogen genomic data. We used a nested cross validation design, population structure control, and recursive feature selection to improve model performance and showed that incorporating population structure control was crucial for improving model interpretation and generalizability. Our best model, controlling for population structure and using only 30 recursively selected features, had an area under the curve of 0.87 for a holdout test dataset. The top-ranked features were generally associated with motility, adhesion, and biofilm formation.

Indexed as

Cystic FibrosisPseudomonas InfectionsAnti-Bacterial AgentsCell AggregationChildHumansLungPseudomonas aeruginosaAnti-Bacterial Agents

Identifiers

PMID37672526
PMCPMC10506723
OpenAlexW4386470099

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.